CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,105 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
CanSino Biologics Inc 的 CEO 是谁？
Mr. Xuefeng Yu 是 CanSino Biologics Inc 的 Executive Chairman of the Board，自 2009 加入公司。
CASBF 股票的价格表现如何？
CASBF 的当前价格为 $6.6，在上个交易日 decreased 了 0%。
CanSino Biologics Inc 的主要业务主题或行业是什么？
CanSino Biologics Inc 属于 Biotechnology 行业，该板块是 Health Care
